Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio-N-arylacetamides as novel HSP90 C-terminal inhibitors

References

• Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther. 2004;3(8):1021–1030.
   PubMed Web of Science ®Google Scholar
• Birbo B, Madu EE, Madu CO, Jain A, Lu Y. Role of HSP90 in cancer. Int J Mol Sci. 2021;22(19):10317.
   PubMed Web of Science ®Google Scholar
• Miyata Y, Nakamoto H, Neckers L. The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des. 2013;19(3):347–365.
   PubMed Web of Science ®Google Scholar
• Serwetnyk MA, Blagg BSJ. The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition. Acta Pharm Sin B. 2021;11(6):1446–1468.
   PubMed Web of Science ®Google Scholar
• Ortiz AG, Salcedo JM. Heat shock proteins as targets in oncology. Clin Transl Oncol. 2010;12(3):166–173.
   PubMed Web of Science ®Google Scholar
• Liu Q, Tu G, Hu Y, Jiang Q, Liu J, Lin S, Yu Z, Li G, Wu X, Tang Y, et al. Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer. Eur J Med Chem. 2022;228:114013.
   PubMed Web of Science ®Google Scholar
• Solárová Z, Mojžiš J, Solár P. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review). Int J Oncol. 2015;46(3):907–926.
   PubMed Web of Science ®Google Scholar
• Li ZN, Luo Y. HSP90 inhibitors and cancer: prospects for use in targeted therapies (review). Oncol Rep. 2023;49(1):6.
   PubMed Web of Science ®Google Scholar
• Smyth T, Van Looy T, Curry JE, Rodriguez-Lopez AM, Wozniak A, Zhu M, Donsky R, Morgan JG, Mayeda M, Fletcher JA, et al. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumour models. Mol Cancer Ther. 2012;11(8):1799–1808.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade-Lauraine E, Cassier PA, Moll UM, Ulmer H, Leunen K, et al. Part I of GANNET53: a European multicenter phase I/II trial of the Hsp90 inhibitor ganetespib combined with weekly paclitaxel in women with high-grade, platinum-resistant epithelial ovarian cancer-a study of the GANNET53 consortium. Front Oncol. 2019;9:832.
   PubMed Web of Science ®Google Scholar
• Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80–93.
   PubMed Web of Science ®Google Scholar
• Ewers KM, Patil S, Kopp W, Thomale J, Quilitz T, Magerhans A, Wang X, Hessmann E, Dobbelstein M. HSP90 inhibition synergizes with cisplatin to eliminate basal-like pancreatic ductal adenocarcinoma cells. Cancers. 2021;13(24):6163.
   PubMed Web of Science ®Google Scholar
• Park JM, Kim YJ, Park S, Park M, Farrand L, Nguyen CT, Ann J, Nam G, Park HJ, Lee J, et al. A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer. Mol Cancer. 2020;19(1):161.
   PubMed Web of Science ®Google Scholar
• Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, et al. Combined BRAF and HSP90 inhibition in patients with unresectable BRAF (V600E)-mutant melanoma. Clin Cancer Res. 2018;24(22):5516–5524.
   PubMed Web of Science ®Google Scholar
• Li L, Chen NN, You QD, Xu XL. An updated patent review of anticancer Hsp90 inhibitors (2013-present). Expert Opin Ther Pat. 2021;31(1):67–80.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Liu Y. Recent advances in the discovery of novel HSP90 inhibitors: an update from 2014. Curr Drug Targets. 2020;21(3):302–317.
   PubMed Web of Science ®Google Scholar
• Koren J, Blagg BSJ. The right tool for the job: an overview of Hsp90 Inhibitors. Adv Exp Med Biol. 2020;1243:135–146.
   PubMed Web of Science ®Google Scholar
• Bickel D, Gohlke H. C-terminal modulators of heat shock protein of 90 kDa (HSP90): state of development and modes of action. Bioorg Med Chem. 2019;27(21):115080.
   PubMed Web of Science ®Google Scholar
• Byrd JC. HSP90 inhibition without heat shock response. Blood. 2018;132(3):241–242.
   PubMed Web of Science ®Google Scholar
• Li L, Wang L, You QD, Xu XL. Heat shock protein 90 inhibitors: an update on achievements, challenges, and future directions. J Med Chem. 2020;63(5):1798–1822.
   PubMed Web of Science ®Google Scholar
• Liew HY, Tan XY, Chan HH, Khaw KY, Ong YS. Natural HSP90 inhibitors as a potential therapeutic intervention in treating cancers: a comprehensive review. Pharmacol Res. 2022;181:106260.
   PubMed Web of Science ®Google Scholar
• Matts RL, Dixit A, Peterson LB, Sun L, Voruganti S, Kalyanaraman P, Hartson SD, Verkhivker GM, Blagg BS. Elucidation of the Hsp90 C-terminal inhibitor binding site. ACS Chem Biol. 2011;6(8):800–807.
   PubMed Web of Science ®Google Scholar
• Khalid S, Paul S. Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: a plausible therapeutic approach in Alzheimer’s disease. Med Hypotheses. 2014;83(1):39–46.
   PubMed Web of Science ®Google Scholar
• Morra G, Neves MAC, Plescia CJ, Tsustsumi S, Neckers L, Verkhivker G, Altieri DC, Colombo G. Dynamics-based discovery of allosteric inhibitors: selection of new ligands for the C-terminal domain of Hsp90. J Chem Theory Comput. 2010;6(9):2978–2989.
   PubMed Web of Science ®Google Scholar
• Sgobba M, Degliesposti G, Ferrari AM, Rastelli G. Structural models and binding site prediction of the C-terminal domain of human Hsp90: a new target for anticancer drugs. Chem Biol Drug Des. 2008;71(5):420–433.
   PubMed Web of Science ®Google Scholar
• Giordano D, Biancaniello C, Argenio MA, Facchiano A. Drug design by pharmacophore and virtual screening approach. Pharmaceuticals. 2022;15(5):646.
   Web of Science ®Google Scholar
• Tomašič T, Durcik M, Keegan BM, Skledar DG, Zajec Ž, Blagg BSJ, Bryant SD. Discovery of novel Hsp90 C-terminal inhibitors using 3D-pharmacophores derived from molecular dynamics simulations. Int J Mol Sci. 2020;21(18):6898.
   PubMed Web of Science ®Google Scholar
• Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem. 2000;275(47):37181–37186.
   PubMed Web of Science ®Google Scholar
• Kusuma BR, Khandelwal A, Gu W, Brown D, Liu W, Vielhauer G, Holzbeierlein J, Blagg BS. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors. Bioorg Med Chem. 2014;22(4):1441–1449.
   PubMed Web of Science ®Google Scholar
• Garg G, Forsberg LK, Zhao H, Blagg BSJ. Development of phenyl cyclohexylcarboxamides as a novel class of Hsp90 C-terminal inhibitors. Chemistry. 2017;23(65):16574–16585.
   PubMed Web of Science ®Google Scholar
• Hyun SY, Le HT, Nguyen CT, Yong YS, Boo HJ, Lee HJ, Lee JS, Min HY, Ann J, Chen J, et al. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer. Sci Rep. 2018;8(1):13924.
   PubMedGoogle Scholar
• Jiang F, Guo AP, Xu JC, Wang HJ, Mo XF, You QD, Xu XL. Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors. Eur J Med Chem. 2017;141:1–14.
   PubMed Web of Science ®Google Scholar
• Chang DJ, An H, Kim KS, Kim HH, Jung J, Lee JM, Kim NJ, Han YT, Yun H, Lee S, et al. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis. J Med Chem. 2012;55(24):10863–10884.
   PubMed Web of Science ®Google Scholar
• Kim HS, Hong M, Ann J, Yoon S, Nguyen CT, Lee SC, Lee HY, Suh YG, Seo JH, Choi H, et al. Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors. Bioorg Med Chem. 2016;24(22):6082–6093.
   PubMed Web of Science ®Google Scholar
• Mir F, Shafi S, Zaman MS, Kalia NP, Rajput VS, Mulakayala C, Mulakayala N, Khan IA, Alam MS. Sulfur rich 2-mercaptobenzothiazole and 1,2,3-triazole conjugates as novel antitubercular agents. Eur J Med Chem. 2014;76:274–283.
   PubMed Web of Science ®Google Scholar
• Kurop MK, Huyen CM, Kelly JH, Blagg BSJ. The heat shock response and small molecule regulators. Eur J Med Chem. 2021;226:113846.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013;14(9):e358–e369.
   PubMed Web of Science ®Google Scholar
• Amatya E, Blagg BSJ. Recent advances toward the development of Hsp90 C-terminal inhibitors. Bioorg Med Chem Lett. 2023;80:129111.
   PubMed Web of Science ®Google Scholar
• Peng S, Woodruff J, Pathak PK, Matts RL, Deng J. Crystal structure of the middle and C-terminal domains of Hsp90α labeled with a coumarin derivative reveals a potential allosteric binding site as a drug target. Acta Crystallogr D Struct Biol. 2022;78(Pt 5):571–585.
   PubMedGoogle Scholar
• Yang M, Li C, Li Y, Cheng C, Shi M, Yin L, Xue H, Liu Y. Design, synthesis, biological evaluation and molecular docking study of 2, 4-diarylimidazoles and 2, 4-bis (benzyloxy)-5-arylpyrimidines as novel HSP90 N-terminal inhibitors. J Enzyme Inhib Med Chem. 2022;37(1):2551–2565.
   PubMedGoogle Scholar